{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-033054","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.354896+00:00","generated_at":"2026-06-18T00:42:26.601846+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients","bullets":["Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.","Q4 net loss $3.3M ($0.28/share) vs $2.6M ($0.26); FY net loss $12.1M ($1.12) vs $12.7M ($1.49).","R&D expense FY2022 $4.8M (up from $2.0M) due to Phase 2b costs; G&A $7.3M (down from $10.8M).","Phase 2b CDI trial has enrolled 25 of 36 patients needed for IDMC interim review; IDMC may recommend early termination or continue enrollment.","Non-dilutive grant application for $11.3M for ACX-375 (MRSA) in final round; decision expected in April 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-033054","json":"https://secwatch.observer/filing/0001104659-23-033054.json","markdown":"https://secwatch.observer/filing/0001104659-23-033054.md","text":"https://secwatch.observer/filing/0001104659-23-033054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/0001104659-23-033054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/tm239317-2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:42:26.601846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}